ORG
The Future of Healthcare: Embracing Omnichannel Care for Seamless Patient Experience
Omnichannel care, Telehealth, Healthcare technology, Patient-centric care, Integrated healthcare delivery, Virtual care, In-person care, Healthcare innovation, Digital health, Healthcare trends
Unlocking Direct-to-Consumer (DTC) Adoption: Leveraging Telehealth Programs for Enhanced Healthcare Access” ###
Direct-to-Consumer (DTC) digital health, Telehealth adoption, Virtual care platforms, Clinical networks, Consumer health and pharma leaders, Telemedicine services, Healthcare consumption, Primary care, Reimbursement models, Policy perspectives
FDA Approves Tris Pharma’s Onyda XR, First Liquid Non-Stimulant ADHD Medication for Pediatric Patients ###
Tris Pharma, Onyda XR, ADHD, Non-stimulant, Liquid medication, Pediatric patients, FDA approval, Clonidine hydrochloride, Extended-release oral suspension, LiquiXR technology
BioNTech Secures $145M from CEPI to Expand mRNA Vaccine Production in Africa
BioNTech, CEPI, mRNA vaccine production, Africa, vaccine equity, public health security
Regulatory Tracker: Lilly’s Retevmo Secures Pediatric Cancer FDA Nod ###
Retevmo, Eli Lilly, FDA approval, pediatric cancer, RET-altered, thyroid cancer, solid tumors, accelerated approval, LIBRETTO-121 trial, selpercatinib
Immunovant Shifts Focus to Next-Generation FcRn Inhibitor IMVT-1402, Delaying Batoclimab Development ###
Immunovant, IMVT-1402, FcRn inhibitor, Batoclimab, Autoimmune diseases, Vyvgart, Roivant, Biopharmaceuticals
Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering
Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis
Merck & Co. Revives Ophthalmology Efforts with $3 Billion EyeBio Acquisition ###
Merck & Co., EyeBio, Ophthalmology, Trispecific antibody, Restoret, Acquisition, Biotechnology, Pharmaceuticals
ExpressionEdits Secures $13M in Seed Funding to Revolutionize Protein Therapies with AI-Driven Intronization Technology
ExpressionEdits, Protein therapies, AI-driven intronization technology, Seed funding, Biotechnology, Protein expression
FDA Approves Amgen’s Bkemv, First Interchangeable Biosimilar to Soliris for Rare Blood Disorders ###
Bkemv, Soliris, FDA approval, Interchangeable biosimilar, Rare blood disorders, Paroxysmal nocturnal hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (aHUS), Amgen, AstraZeneca, Alexion Pharmaceuticals